SYRS - Syros Average Forecast Price

Symbol and logo of brand Syros (SYRS)

The price trend for Syros Pharmaceuticals (SYRS) demonstrates the current indicator 8.73. This biopharmaceutical startup implements a method of reprogramming malignant cell functions to restore their health. The company's revenues are intended to be based on the sale of gene therapies for leukemia; however, the failure of the final stage of tests for its lead product destroyed its competitive advantages, pushing the firm to the brink of bankruptcy due to a capital shortage.

SYRS: Syros Pharmaceuticals, Inc. Price Target Chart 07/04/2022 - 03/29/2025
Manufactured products of syros.com

The investment attractiveness of Syros Pharmaceuticals (SYRS) is based on the platform's ability to create precision medicines through the management of gene expression. The trend in analysts' consensus price targets reflects the speed at which the market is repricing these technological achievements, capturing a gap where target prices exceed the current share price. The growth of this indicator confirms the company's fundamental strength and the adaptation of institutional valuations to its genetic leadership.

Competitors of Syros Pharmaceuticals

Analyst Median Target tempus.com|Qiagen - Consensus Target|Ionis Pharmaceuticals, Inc. (IONS) - Average Forecast Price|RGEN - Price Target Chart|Fair Value Consensus RNA (Avidity Corp)|CRISPR Therapeutics AG (CRSP) - Price Target Chart|WGS - Analyst Median Target|RARE (Ultragenyx) - Analyst Consensus Forecast|Broker Consensus Forecast BEAM (Beam Therapeutics Inc)|Price Target Chart Sarepta Therapeutics Inc (SRPT)|Twist Bioscience Corp - Broker Consensus Forecast|Analyst Consensus Forecast TXG (10x Genomics, Inc.)|Analyst Consensus Forecast intelliatx.com NTLA|STOK - Price Target Chart|Analyst Median Target BioLife Solutions Inc BLFS|WVE (Wave Life Sciences Corp) - Consensus Target|Average Forecast Price Maze Therapeutics Corp (MAZE)|Price Target Chart Sionna Therapeutics Inc|PRME: Fair Value Consensus|Price Target Chart Taysha Gene Therapies, Inc. (TSHA)|QURE - Average Forecast Price|Price Target Chart MeiraGTx PLC MGTX|Analyst Median Target REGENXBIO Corp (RGNX)|SLDB: Consensus Target|Fair Value Consensus OCGN (ocugen.com)|PacBio (PACB) - Price Target Chart|Forecast Levels Chart BNTC (Benitec Biopharma Inc)|DSGN (Design Pharma) - Analyst Consensus Forecast|RCKT: Fair Value Consensus|Analyst Consensus Forecast FDMT|Analyst Consensus Forecast lexeotx.com (LXEO)|Price Target Chart Korro Bio KRRO|Fair Value Consensus EDIT|SLN - Price Target Chart|ProQR Therapeutics N.V. (PRQR) - Consensus Target|CDXS: Analyst Consensus Forecast|sangamo.com (SGMO) - Analyst Consensus Forecast|NAUT (Nautilus Biotechnology, Inc.) - Analyst Consensus Forecast|Consensus Target Metagenomi Inc. (MGX)|Analyst Consensus Forecast DTIL|GBIO - Average Forecast Price|Boundless Bio, Inc. - Consensus Target|Analyst Consensus Forecast Exicure Inc. XCUR|IMNN: Consensus Target|Phio Pharmaceuticals - Analyst Forecast Prices|MBIO: Analyst Consensus Forecast|RNAZ - Analyst Median Target|BNGO (Bionano Genomics Inc.) - Analyst Consensus Forecast|Consensus Target adnas.com (APDN)|Analyst Consensus Forecast BLUE|Analyst Consensus Forecast immunoprecise.com (IPA)|Price Target Chart Omega OMGA|Singular Genomics Corp - Price Target Chart|RGLS - Price Target Chart|Analyst Median Target telesisbio.com TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Price Target Chart|UBX - Analyst Median Target